The effects of thromboxane antagonism on the transit time of platelets through the spleen.
The spleen is well-known as a site for platelet pooling, although the mechanisms controlling intrasplenic platelet transit are essentially unknown. We tested the possibility that thromboxane A2 might be involved in this control by measuring intrasplenic platelet transit time in 10 subjects receiving a specific thromboxane A2 receptor antagonist (AH23848B; 70 mg; Glaxo Group Research Ltd), in 10 receiving aspirin (300 mg) plus dipyridamole (75 mg), and in 9 receiving placebo. All doses were administered 3 times daily commencing 4 days prior to transit time measurement. Mean intrasplenic platelet transit time was measured by monitoring the kinetics of equilibration of 111In radiolabelled platelets between blood and spleen following intravenous injection. There was no difference between the mean transit time in the 3 groups of subjects, lending no support to the hypothesis that thromboxane A2 is involved in the control of platelet traffic through the spleen.
D000368:Aged; D001241:Aspirin / Q000008:administration & dosage; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D001775:Blood Circulation / Q000187:drug effects*; D001792:Blood Platelets / Q000378:metabolism / Q000502:physiology*; D004176:Dipyridamole / Q000008:administration & dosage; D004311:Double-Blind Method; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011897:Random Allocation; D011982:Receptors, Prostaglandin / Q000187:drug effects; D017482:Receptors, Thromboxane; D013154:Spleen / Q000098:blood supply* / Q000378:metabolism; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors* / Q000378:metabolism
D001713:Biphenyl Compounds; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013928:Thromboxane A2; D004176:Dipyridamole; C046926:AH 23848; D001241:Aspirin